PORTFOLIO 01-02
– In-house development of an innovative device required for a cutting edge cardiac surgical procedure (AVNeo) developed in Japan.
– Distribution contracts signed with partners in 40 countries, currently expanding distribution markets (as of May 2020)
– Product developed in-house (including license from a university)
– See owntissuevalve.org,AVNeo.net ,LinkedIn, and facebook for more on this procedure.
– A stent graft entirely manufactured in Japan, highly competitive and features the concentration of Japanese technologies
– An innovative, graft substrate with a thinner profile, is expected to enable percutaneous delivery
– Joint development with world renowned vascular surgeon, Professor Takao Ohki, and and key Japanese medical device manufacturers, MANI, Inc., and Kawasumi Laboratories, Inc.
– In development / globally unapproved
PORTFOLIO 03
– In development by Dr. Kazuhiro Kawamura, International University of Health and Welfare, Dr. Masashi Ikeuchi, University of Tokyo, and JOMDD
– Our goal of this research is to develop an automatic sperm sorting device which discriminates motility and morphology of sperm cells and automatically sorts the sperm cells that are selected as good-quality sperm
– JOMDD will develop the device to order to aid in the embryologists’ sperm selection and improve workflow
– In development / globally unapproved
PORTFOLIO 04
– In development by MELTIN MMI K.K. (meltin.jp)*MELTIN MMI completed JPY2 billion Series B Financing in 2018
– The fusion of biosignal processing using high precision / real-time algorithms and superior robotics / control technologies
– Realization of cyborg technologies through the Brain Machine Interface, linking brain to artificial body parts
– In development / globally unapproved
PORTFOLIO 05-06
–In development by Luxonus Co. ( https://www.luxonus.jp/en/index.html )
–Fusion of two technologies, ultrasound imaging in the body and high resolution of optical imaging
–Ultra-high resolution 3D imaging of blood vessels and lymph vessels
–Aim to improve treatment results for diseases (vascular disorders, lymphedema, breast cancer, etc.) for which early diagnosis and disease diagnosis were difficult with existing imaging technologies
–The venture company was established on the basis of results from programs including the Japan Science and Technology Agency’s Impulsing Paradigm Change through Disruptive Technology Program (ImPACT)
– In development / globally unapproved
–Launched by Nippon Zoki Pharmaceutical Co., Ltd.(press release: https://jomdd.com/2020/02/2590.html )
–Space Vision, Inc. developed with Keio University.
– LED light source and to capture an image of the patient’s back in 3D and convert it to a mirror image
–Supported by the JMA program, the development and commercialization of medical devices continues to progress (Japan Medical Association)
–Launched in Japan in February 2020 / globally unapproved
–Class I medical device (Japanese registration number 13B1X10274000004)
– See scoliosis-info.jp for more on this procedure.
PORTFOLIO 07
– In development by AWAKENS, Inc. (awakens.co)
– Providing a reliable consumer platform to allow individuals access to their own genomic data
– Developing API software for business and individuals enabling the development of highly reliable integrated genomic services
– Establishing a platform for integrated genomic services worldwide
PORTFOLIO 08
– Being developed by Advanced Laser Technology K.K.
– An OCT observation device that enables unprecedented resolution and depth through innovative light source technology
– In addition to diseases of the fundus such as glaucoma and age-related macular degeneration, it is expected to diagnose neurological diseases (such as Alzheimer’s disease) through the retina
– Not only will it enhance the accuracy of diagnoses, it will contribute to increasing patient QOL and reducing medical expenses by establishing the world’s first non-invasive / early diagnosis method
– In development / globally unapproved
PORTFOLIO 09
– Joint development with P-Mind Co., Ltd. (p-mind.co.jp)
– Theoretically expected to have an effect on all peripheral pain by irradiating the skin in affected areas with distinctive magnetic fields with multiple frequencies under a certain algorithm
– Starting with an indication for fibromyalgia, an intractable disease, treatment indications are expected to expand to include back pain, menstrual pain, joint pain, and pain after the treatment of external injuries
– In the mid- to long-term, seek to expand indications to include diseases of the central nervous system (dementia, mental illness, etc.)
– In development / globally unapproved
PORTFOLIO 10-12
– In development by THINKCYTE, Inc.(thinkcyte.com)*THINKCYTE completed JPY1.6 billion Series A Financing in 2020
– Optical technology enabling high speed / high sensitivity cell and bacterial analysis
– Quantitative assessment of cells – abnormal cells, color, and N/C ratio (can be applied to cancer, cytology, and analysis of intestinal bacteria)
– Uses machine learning to detect abnormal cells
– Developing a support system in line with the test conditions of actual physicians and medical technologists from the “perspective of healthcare professionals”
– In development / globally unapproved
– Measures the level of ADAMTS5 mRNA expression in the blood prior to administration of biological drugs
–Not only does it have the merit of protecting patients from the side effects of ineffective drugs, it will also contribute to reducing medical expenses and may become effective precision medicine
– In development / globally unapproved
– A new method for diagnosing rheumatoid arthritis based on the fact that talin, a protein that is expressed in the regions of cell-cell contact in lymphocytes, is expressed in the short form (short talin) in the blood of patients with rheumatoid arthritis
– May have superior sensitivity and specificity compared with conventional methods for diagnosing rheumatoid arthritis
– Distribution began in the U.S. from September 2017 for research use only (RUO)
– In development / globally unapproved
PORTFOLIO 13-14
– In development by Save Medical Corporation (http://savemedical.jp).
– Save Medical, established in May 2018 as a digital health focused subsidiary of JOMDD
– In 2020, Save Medical executed a capital increase through third-party allocation, and Save Medical and Sumitomo Dainippon Pharma have reached an agreement to jointly develop a mobile app for the diabetes management for patients with type 2 diabetes and that Save Medical has commenced a clinical study for the App in Japan. This clinical study is the first of its kind in Japan.
“Hippocra×mynavi” Clinical Support Tool for Medical Doctor
– Being provided by exMedio Inc. (exmed.io)*Mynavi Corporation has acquired and made a subsidiary of exMedio Inc. in 2019
– A clinical consultation service that links specialists with non-specialists, a cross specialty introduction service
– Consultation requests can be made at any time, 24 hours per day, via smartphone / PC, and responses are received in approximately 30 minutes
– Service currently being provided in the dermatology and ophthalmology areas
– Enables the sharing of insights on treatment among physicians, discussions regarding the effects of a drug, searches for the latest papers, and viewing the latest medical news
PORTFOLIO 15-17
“True Puncture®” Ultrasound-guided Puncture Supporter
– A device that enables practitioners to confirm appropriate line of sight, needle positioning and angle by placing a mirror on the puncture adapter ((click here for reference information))
– An innovative guide system that enables a straight insertion of needles even for punctures made directly from the side
– For the purpose of preventing the incorrect insertion of catheters
– Can be applied in cardiovascular, cardiac surgery, vascular surgery, and tumor-related surgeries (gastrointestinal surgery, respiratory surgery, breast surgery), orthopedic surgery, nephrology, etc.
– Class I medical device (Japanese registration number 8876083023)
Hospitality ONE
– Developed and provided by Hospitality One K.K. (hospitality-one.co.jp)
– A non-insured visiting nurse service with the mission to “create moments of peace” for many
– Currently developing a web-based service, “Discharge Support Navi”, for efficient collaboration between hospitals and visiting nurse stations
“MIRAI SPEAKER” by SoundFun
– Developed and provided by SoundFun Inc. (soundfun.co.jp)
– Speakers capable of clearly delivering information through sound to the ears of many with “curved sound” that generates sound from the entire curved diaphragm speaker with little attenuation or loss of clarity compared with conventional speakers.
– Is being adopted by major corporations including Japan Airlines, Nomura Securities, Resona Bank.
– Cooperative research: Chiba University, The University of Tokyo, Waseda University, Tokyo Metropolitan University
– Patent: 7 domestic patents, 8 overseas patents acquired, PCT world patents and Taiwan patents applied.